Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia - PubMed (original) (raw)
Clinical Trial
doi: 10.1093/jac/dkh356. Epub 2004 Jul 21.
Affiliations
- PMID: 15269191
- DOI: 10.1093/jac/dkh356
Clinical Trial
Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia
Guy Tellier et al. J Antimicrob Chemother. 2004 Aug.
Abstract
Objectives: This study was conducted to investigate the potential equivalence in clinical efficacy and assess safety of a 5 or 7 day regimen of oral telithromycin (800 mg once daily) and a 10 day regimen of oral clarithromycin (500 mg twice daily) in treating community-acquired pneumonia (CAP). Bacteriological efficacy was also compared.
Methods: This was a multicentre, randomized, double-blind, active-controlled study. Patients with mild to moderate CAP received telithromycin 800 mg once a day for 5 (n=193) or 7 (n=195) days or clarithromycin 500 mg twice a day for 10 days (n=187). In these groups, 159, 161 and 146 patients, respectively, completed the study.
Results: At the post-therapy/test-of-cure evaluation, clinical cure rates (per-protocol clinical population) were 89.3% (5 days) and 88.8% (7 days) for telithromycin, and 91.8% for clarithromycin 10 days. Satisfactory bacteriological outcome rates (per-protocol bacteriological population) were 87.7% and 80.0% for 5 and 7 days of telithromycin, respectively, and 83.3% for 10 days of clarithromycin. Bacteriological eradication rates in the respective treatment groups were, for Streptococcus pneumoniae, 95.8% (23/24), 96.7% (29/30) and 88.5% (23/26); for Haemophilus influenzae, 88.0% (22/25), 84.0% (21/25) and 88.2% (15/17) and for Moraxella catarrhalis, 1/1, 4/5 and 3/4. Both telithromycin regimens demonstrated clinical efficacy against pneumococcal bacteraemia (19/19), atypical pathogens (9/9) and erythromycin-resistant S. pneumoniae isolates (5/5). Most treatment-emergent adverse events were mild to moderate in intensity with most commonly reported adverse events involving the gastrointestinal system.
Conclusions: Telithromycin 800 mg administered once a day for 5 or 7 days was as effective and safe as clarithromycin 500 mg administered twice a day for 10 days in treating patients with CAP caused by common respiratory pathogens, including macrolide-resistant isolates, and pneumococcal bacteraemia.
Similar articles
- Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults.
Mathers Dunbar L, Hassman J, Tellier G. Mathers Dunbar L, et al. Clin Ther. 2004 Jan;26(1):48-62. doi: 10.1016/s0149-2918(04)90005-7. Clin Ther. 2004. PMID: 14996517 Clinical Trial. - Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days.
Tellier G, Chang JR, Asche CV, Lavin B, Stewart J, Sullivan SD. Tellier G, et al. Curr Med Res Opin. 2004 May;20(5):739-47. doi: 10.1185/030079904125003610. Curr Med Res Opin. 2004. PMID: 15140341 Clinical Trial. - Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin.
Niederman MS, Chang JR, Stewart J, Nusrat R, Nieman RB. Niederman MS, et al. Curr Med Res Opin. 2004 May;20(5):749-56. doi: 10.1185/030079904125003601. Curr Med Res Opin. 2004. PMID: 15140342 Clinical Trial. - Telithromycin.
Wellington K, Noble S. Wellington K, et al. Drugs. 2004;64(15):1683-94; discussion 1695-6. doi: 10.2165/00003495-200464150-00006. Drugs. 2004. PMID: 15257629 Review. - Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review.
Fogarty CM, Buchanan P, Aubier M, Baz M, van Rensburg D, Rangaraju M, Nusrat R. Fogarty CM, et al. Int J Infect Dis. 2006 Mar;10(2):136-47. doi: 10.1016/j.ijid.2005.01.003. Epub 2005 Sep 22. Int J Infect Dis. 2006. PMID: 16183318 Review.
Cited by
- Identifying the Best Initial Oral Antibiotics for Adults with Community-Acquired Pneumonia: A Network Meta-Analysis.
Kurotschka PK, Bentivegna M, Hulme C, Ebell MH. Kurotschka PK, et al. J Gen Intern Med. 2024 May;39(7):1214-1226. doi: 10.1007/s11606-024-08674-1. Epub 2024 Feb 15. J Gen Intern Med. 2024. PMID: 38360961 - Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis.
Furukawa Y, Luo Y, Funada S, Onishi A, Ostinelli E, Hamza T, Furukawa TA, Kataoka Y. Furukawa Y, et al. BMJ Open. 2023 Mar 22;13(3):e061023. doi: 10.1136/bmjopen-2022-061023. BMJ Open. 2023. PMID: 36948555 Free PMC article. - Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial.
von Dach E, Albrich WC, Brunel AS, Prendki V, Cuvelier C, Flury D, Gayet-Ageron A, Huttner B, Kohler P, Lemmenmeier E, McCallin S, Rossel A, Harbarth S, Kaiser L, Bochud PY, Huttner A. von Dach E, et al. JAMA. 2020 Jun 2;323(21):2160-2169. doi: 10.1001/jama.2020.6348. JAMA. 2020. PMID: 32484534 Free PMC article. Clinical Trial. - Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) randomised clinical trial: study protocol.
Daneman N, Rishu AH, Pinto RL, Arabi YM, Cook DJ, Hall R, McGuinness S, Muscedere J, Parke R, Reynolds S, Rogers B, Shehabi Y, Fowler RA; Canadian Critical Care Trials Group. Daneman N, et al. BMJ Open. 2020 May 11;10(5):e038300. doi: 10.1136/bmjopen-2020-038300. BMJ Open. 2020. PMID: 32398341 Free PMC article. - Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. Metlay JP, et al. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST. Am J Respir Crit Care Med. 2019. PMID: 31573350 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous